4-(1-(tert-Butoxycarbonyl)azetidin-3-yl)benzoic acid, 95.0%, 100mg

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anisole>98.0%(GC)(T)25g

Palbociclib hydrochloride, 95%, 500mg

4,4'-Bipyridine -1,1'-dioxide, 97.0%, 10g

N'-[4-(4-Bromo-1-ethyl-1H-pyrazol-3-yl)phenyl]-N,N-dimethylurea, 97%, 1g

tert-Butyl (2R,4S)-2,4-bis(hydroxymethyl)azetidine-1-carboxylate, 97%, 1g

Diethyl 5-aminoisophthalate hydrochloride, 98%, 1g

1-(Trifluoromethyl)-N-methylcyclopropylamine, 98%, 1g

2-CHLORO-4-FLUORO-5-IODOPYRIDINE, 95.0%, 100mg

2-Amino-4,5-dichlorobenzaldehyde, 95.0%, 100mg

2,6-Difluoro-3-phenylbenzaldehyde, 98%, 500mg

Closing caps, Gesch. front, Ø 38 mm 250 pcs

2-ethyl-5-(4H-1,2,4-triazol-4-yl)aniline, 95.0%, 5g